Citadel Advisors
CYCN icon

Citadel Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Citadel Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,290
Closed -$80.6K – 14458
2023
Q1 		$80.6K Sell
9,290
-3,150
-25% -$39.7K ﹤0.01% 11546
2022
Q4 		$163K Buy
12,440
+305
+3% +$3.61K ﹤0.01% 10474
2022
Q3 		$209K Buy
12,135
+110
+0.9% +$1.89K ﹤0.01% 10317
2022
Q2 		$132K Buy
12,025
+4,875
+68% +$69.8K ﹤0.01% 11107
2022
Q1 		$159K Sell
7,150
-2,590
-27% -$62.4K ﹤0.01% 11787
2021
Q4 		$335K Buy
9,740
+1,875
+24% +$88.6K ﹤0.01% 10681
2021
Q3 		$483K Buy
7,865
+4,800
+157% +$314K ﹤0.01% 9954
2021
Q2 		$239K Buy
3,065
+2,045
+200% +$128K ﹤0.01% 11783
2021
Q1 		$57K Buy
+1,020
New +$76.6K ﹤0.01% 12837
2020
Q4 		– Sell
-590
Closed -$72K – 10988
2020
Q3 		$72K Buy
+590
New +$67.5K ﹤0.01% 9450

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Citadel Advisors's CYCN Position: Q1 2026 in Review

Citadel Advisors opened a new position in Cyclerion Therapeutics (CYCN) in Q1 2026: 18,261 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #12592 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CYCN as recently as Q3 2022.

Citadel Advisors first reported a position in CYCN in Q2 2019 and has held it in 8 quarters since. The position peaked at $3.42M in Q2 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Citadel Advisors held 18,261 shares of Cyclerion Therapeutics worth $28K as of Q1 2026.
  • Cyclerion Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12592 holding.
  • Citadel Advisors first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 8 quarters since.
  • Citadel Advisors's Cyclerion Therapeutics position peaked at $3.42M in Q2 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.